Skip to main content
KBS_Icon_questionmark link-ico


Dr Huajie Jin (Lily) is a Senior Lecturer in Health Economics at the Health Service and Population Research Department at the Institute of Psychiatry, Psychology and Neuroscience at King’s College London (KCL).

Lily gained a BSc in Medicine in the People’s Republic of China in 2008 and completed her MSc in International Health Policy (health Economics stream) at the London School of Economics and Political Science in 2009. Following the completion of her MSc, she worked on the National Institute for Health and Care Excellence (NICE) clinical guidelines for three years: first year as a systematic reviewer, second and third year as a health economist. Since Lily joined KCL in 2013 as a senior health economist, she has been working on a part-time PhD, which aims to build an individual patient level whole disease model covering the entire care pathway for schizophrenia service in the UK. Lily gained her PhD from KCL in 2019 and was awarded “PhD of the year” in Health Service and Population Research Department. Lily was promoted to a Senior Lecturer in Health Economics at KCL in Sep 2021.

Lily is a health economic advisor to the scrutiny panel for planned care in Wales from June 2021. Lily was an Honorary Research Fellow of the Medical Department, Cardiff University (2011-2013). She was also an Honorary Research Associate at the Swansea Centre for Health Economics, Swansea university (2012-2013).

Lily was the principal health economist of three NICE clinical guidelines and three NICE Medtech innovation briefings (MIBs).

Lily is a member of the following groups:

  • International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
  • UK Health Economists' Study Group (HESG)
  • Operational Research (OR) Society

Lily is currently leading the health economic analysis for the following projects:

  • PROSPECTS ( A 7-year multi-centre clinical trial which aims to compare the cost-effectiveness of breast cancer screening using DBT + 2DDM or S2D with screening using 2DDM, based on data for 100,000 women aged 50-70 years who are attending routine breast screening.
  • STARRT-AKI ( A 7-year multinational clinical trial which aims to compare the cost-effectiveness of accelerated initiation of renal replacement therapy compared to standard initiation in 2,927 critically ill patients with severe acute kidney injury.
  • YouScreen ( A 3-year pragmatic implementation feasibility clinical trial which aims to compare the cost-effectiveness of vaginal self-sampling with the standard call/recall system based on data for 31,000 women and people with a cervix in north and east London.

Research Interests

Lily has thirteen years of work experience in health economic evaluation, including model-based and/or trial-based economic evaluation, cost-of-illness study and budget-impact analysis. She is particularly interested in the development and reuse of whole disease models. She has been working on a wide range of different disease areas, including mental health disorders, cancers, kidney diseases, infectious diseases, and orthodontics.

Her research interests are:

  • Health Technology Assessment
  • Cost-effectiveness/utility analysis
  • Budget impact analysis
  • Cost-of-illness study
  • Health economic modelling (e.g., decision tree, Markov model, and discrete event simulation)
  • Whole disease modelling
  • Trial-based economic evaluation

Lily welcomes PhD applications about applied and/or methodological research related to health economic evaluation.


  • Second PhD supervisor – Dr. David Aceituno, KCL (2021-Present); Project Title: Cost-effectiveness of implementing Early Intervention in Psychosis services in Latin America; With: Dr. Matthew Prina and Dr. Mark Pennington
  • Second PhD supervisor – Mr. Darren Lui, KCL (2021-Present); Project Title: Pharmacoeconomic Considerations for Early-Stage Drug R&D Pharmaceutical Management Decision Making; With: Dr. Renee Romeo
  • Primary supervisor to PhD exchange student – Dr. Wenru Shang, Fudan University (2020-2021); Project Title: Cost effectiveness of repeat delayed imaging for spontaneous subarachnoid hemorrhage
  • Second MSc supervisor – Dr. Owen Jermyn, KCL (2020-Present); Project Title: Cost-Effectiveness of Orthodontics: A Systematic Review; With: Prof. Dirk Bister 

Expertise and Public Engagement 

Public engagement

  • 2021 - present: Health economic advisor to the scrutiny panel for planned care in Wales.
  • 2013 - present: Peer view papers for a range of journals, including The Lancet Infectious Disease, The Lancet Global Health, The Lancet Public Health, Bulletin of the World Health Organization, Value in Health and PharmacoEconomics etc.

Selection of recent public presentations

  • Dec 2021. Oral presentation “Use of Whole Disease Models (WDM) and Pathway Models in Health Economic Research — Benefits and Risks” at Virtual ISPOR Europe 2021, Milan, Italy.
  • June 2021. Paper accepted for oral discussion at HESG – “Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies”, online conference, Cambridge, UK.
  • June 2021. Oral presentation of “The use and value of Whole Disease Modelling Approach in HTA” at Shanghai HTA centre, online seminar, Shanghai, China.
  • Nov 2020. Oral presentation of spotlight session “Novel Methods for Modelling Treatment Sequencing” at Virtual ISPOR Europe 2020, Milan, Italy.
  • Aug 2020. Oral presentation of “Introducing the Whole Disease Modelling (WDM) Approach Online Seminar” at the Health Intervention and Technology Assessment Program (Hitap) online seminar, Nonthaburi, Thailand.
  • Jan 2020. Oral presentation of the findings of the schizophrenia whole disease model at the Health Economics and Decision Science (HEDS) seminar, the University of Sheffield, Sheffield, UK.
  • Sep 2019. Oral presentation of the findings of the schizophrenia whole disease model at the Health Economics Research Centre (HERC) Seminar Series, University of Oxford, UK.